Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
NRXS Neuraxis
- 2.340
- -0.077-3.18%
Trading Apr 24 11:06 ET
16.89MMarket Cap-1.92P/E (TTM)
2.490High2.300Low26.51KVolume2.410Open2.417Pre Close63.59KTurnover0.60%Turnover RatioLossP/E (Static)7.22MShares3.78052wk High8.15P/B10.41MFloat Cap1.33052wk Low--Dividend TTM4.45MShs Float6.930Historical High--Div YieldTTM7.86%Amplitude1.330Historical Low2.398Avg Price1Lot Size
Neuraxis Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.18%2.69M | 43.22%761.17K | 39.62%666.63K | -5.34%611.5K | -19.68%646.64K | -8.37%2.46M | -13.31%531.46K | -22.84%477.46K | -5.36%646.02K | 4.52%805.11K |
| Operating revenue | 9.18%2.69M | 43.22%761.17K | 39.62%666.63K | -5.34%611.5K | -19.68%646.64K | -8.37%2.46M | -13.31%531.46K | -22.84%477.46K | -5.36%646.02K | 4.52%805.11K |
| Cost of revenue | 19.34%362K | 45.21%105.05K | 44.23%97.05K | 8.32%73.46K | -21.71%75.08K | 2.12%303.35K | -3.81%72.35K | -0.52%67.29K | -14.17%67.81K | 27.53%95.9K |
| Gross profit | 7.75%2.32M | 42.91%656.11K | 38.86%569.58K | -6.95%538.04K | -19.41%571.55K | -9.67%2.16M | -14.64%459.11K | -25.58%410.17K | -4.20%578.21K | 2.03%709.21K |
| Operating expense | 7.48%9.48M | 1.94%2.12M | -35.30%2.22M | 61.87%2.74M | 49.72%2.4M | 53.15%8.82M | 36.63%2.08M | 95.66%3.43M | 33.19%1.7M | 32.86%1.61M |
| Selling and administrative expenses | 7.20%9.27M | -1.71%2.05M | -36.58%2.15M | 69.65%2.69M | 50.95%2.4M | 56.33%8.65M | 44.49%2.08M | 103.08%3.39M | 25.92%1.59M | 36.49%1.59M |
| -Selling and marketing expense | 0.35%324.71K | 35.38%98.33K | 48.62%95.43K | -20.96%62.27K | -25.85%80.03K | -21.25%323.57K | 10.07%72.64K | -21.30%64.21K | -38.17%78.79K | -20.57%107.93K |
| -General and administrative expense | 7.46%8.95M | -3.05%1.95M | -38.23%2.05M | 74.39%2.63M | 56.55%2.32M | 62.55%8.33M | 46.14%2.01M | 109.47%3.32M | 33.13%1.51M | 44.03%1.48M |
| Research and development costs | 21.73%206.11K | 3,422.96%73.8K | 61.12%72.42K | -50.53%54.31K | -66.84%5.57K | -24.95%169.32K | -102.73%-2.22K | -47.84%44.95K | 703.43%109.79K | -62.17%16.8K |
| Operating profit | -7.39%-7.16M | 9.65%-1.47M | 45.36%-1.65M | -97.47%-2.21M | -104.42%-1.83M | -97.63%-6.66M | -64.59%-1.62M | -151.21%-3.02M | -66.90%-1.12M | -74.61%-896.27K |
| Net non-operating interest income expense | 90.08%-531.54K | 90.29%-2.39K | 92.63%-105.56K | 86.65%-144.51K | 90.13%-279.07K | -95.66%-5.36M | 97.71%-24.65K | -99.41%-1.43M | -17.66%-1.08M | -10,731.86%-2.83M |
| Non-operating interest income | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --2.1K | ---- | ---- |
| Non-operating interest expense | -94.39%300.72K | -89.38%2.39K | -92.64%105.56K | -86.65%144.51K | -98.29%48.24K | 1,183.05%5.36M | -90.08%22.55K | 1,127.76%1.43M | 2,184.31%1.08M | 10,721.24%2.82M |
| Total other finance cost | 8,226.98%230.82K | --0 | ---- | ---- | 8,226.98%230.82K | -99.88%2.77K | --0 | ---- | ---- | --2.77K |
| Other net income (expense) | 78.74%-553.15K | -62.06%21.08K | 100.04%1.6K | -1,497.82%-566.36K | -100.61%-9.46K | -295.30%-2.6M | -97.29%55.56K | -2,529.19%-4.17M | -148.42%-35.45K | 580,416.85%1.55M |
| Gain on sale of security | -100.09%-941 | -85.93%7.49K | -101.12%-6.73K | 121.53%7.58K | -102.18%-9.28K | -20.96%1.04M | -97.40%53.24K | 477.69%599.25K | -157.20%-35.19K | --426.1K |
| Special income (charges) | --0 | --0 | --0 | --0 | --0 | ---3.65M | --10 | ---4.78M | --0 | --1.13M |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | --3.65M | ---10 | --4.78M | ---- | ---1.13M |
| Other non- operating income (expenses) | -11,657.22%-552.2K | 490.01%13.59K | -0.29%8.33K | -224,095.31%-573.94K | 96.80%-180 | -60.04%4.78K | --2.3K | --8.35K | -102.19%-256 | -2,205.62%-5.62K |
| Income before tax | 43.65%-8.24M | 9.07%-1.45M | 79.65%-1.76M | -30.51%-2.92M | 2.43%-2.12M | -205.99%-14.63M | -11,584.02%-1.59M | -314.74%-8.63M | -47.42%-2.24M | -303.13%-2.17M |
| Income tax | ||||||||||
| Net income | 43.65%-8.24M | 9.07%-1.45M | 79.65%-1.76M | -30.51%-2.92M | 2.43%-2.12M | -205.99%-14.63M | -11,584.02%-1.59M | -314.74%-8.63M | -47.42%-2.24M | -303.13%-2.17M |
| Net income continuous Operations | 43.65%-8.24M | 9.07%-1.45M | 79.65%-1.76M | -30.51%-2.92M | 2.43%-2.12M | -205.99%-14.63M | -11,584.02%-1.59M | -314.74%-8.63M | -47.42%-2.24M | -303.13%-2.17M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 43.65%-8.24M | 9.07%-1.45M | 79.65%-1.76M | -30.51%-2.92M | 2.43%-2.12M | -205.99%-14.63M | -11,584.02%-1.59M | -314.74%-8.63M | -47.42%-2.24M | -303.13%-2.17M |
| Preferred stock dividends | 211.27K | 0.00%190.7K | ||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 42.21%-8.45M | -4.20%-1.66M | 79.65%-1.76M | -20.25%-2.92M | 2.43%-2.12M | -163.78%-14.63M | -671.38%-1.59M | -279.56%-8.63M | -42.12%-2.43M | -198.65%-2.17M |
| Basic earnings per share | 72.89%-1.22 | 14.16%-0.21 | 89.50%-0.25 | -4.59%-0.42 | 9.60%-0.32 | -398.29%-4.5 | -627.64%-0.2446 | -543.05%-2.38 | -44.42%-0.4016 | -198.65%-0.354 |
| Diluted earnings per share | 72.89%-1.22 | 14.16%-0.21 | 89.50%-0.25 | -4.59%-0.42 | 9.60%-0.32 | -398.29%-4.5 | -627.64%-0.2446 | -543.05%-2.38 | -44.42%-0.4016 | -198.65%-0.354 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now